Table 1.
Summary of Patient Characteristics
| Total number of patients | 63 |
| Male | 47 (74.6%) |
| Female | 16 (25.4%) |
| Age (years), mean ± standard deviation | 60.7 ± 11.3 |
| Previous nephrectomy | 45 (71.4%) |
| Line of treatment | |
| First | 50 (79.4%) |
| Second | 12 (19.1%) |
| Third | 1 (1.6%) |
| Start dose | |
| 25 mg | 1 (1.6%) |
| 37.5 mg | 10 (15.9%) |
| 50 mg | 52 (82.6%) |
| Histology | |
| Clear cell | 43 (68.3%) |
| Sarcomatoid | 1 (1.6%) |
| Chromophobe | 2 (3.2%) |
| Eosinophile | 1 (1.6%) |
| Papillary | 3 (4.8%) |
| Mucinous | 1 (1.6%) |
| Xp11.2 translocation-type renal cell carcinoma, APSL-TFE3 variant | 1 (1.6%) |
| Mixed subtype | 11 (17.5%) |
| ECOG performance status | |
| 0 | 27 (42.9%) |
| 1 | 27 (42.9%) |
| 2 | 7 (11.1%) |
| 3 | 2 (3.2%) |
| Heng risk category | |
| Favorable risk | 6 (9.5%) |
| Intermediate risk | 42 (66.7%) |
| Poor risk | 15 (23.8%) |
| Lesions | 148 |
| Lymph node | 57 (35.5%) |
| Kidney | 22 (14.9%) |
| Liver | 15 (10.1%) |
| Adrenal gland | 12 (8.1%) |
| Pleura | 12 (8.1%) |
| Bone | 11 (7.4%) |
| Intramuscular | 7 (4.7%) |
| Local recurrence | 5 (3.4%) |
| Peritoneum | 4 (2.7%) |
| Pancreas | 2 (1.4%) |
| Spleen | 1 (0.7%) |
| Lesion size (mm), mean ± standard deviation | 42.5 ± 30.6 |